Pricing Experiments: Pharmas Get Creative in Germany
As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. The evolution of these payor-pharma deals in Germany should inform reimbursement strategies elsewhere--including in the US where similar trends are starting to emerge.
You may also be interested in...
For innovator firms, Europe has been about surviving multiple price cuts and government austerity measures. For generics firms, it has become a land of opportunity, where 2011 growth will outpace the overall pharmaceutical market.
Germany's largest insurer AOK has announced the winners of its two-year, price-driven generic supply contracts, but court appeals by disgruntled losers threaten the system.
Spain's drug industry appeals against a court ruling allowing local drug funding decisions.